(Q38989105)

English

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

phase III clinical trial

0 references

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Philip G Conaghan

9

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Désirée van der Heijde

7

object named as

Désirée van der Heijde

0 references

Robert Landewé

8

object named as

Robert Landewé

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Svetlana Yakupova

0 references

Jacek Szepietowski

1 reference

ORCID Public Data File 2021

Arthur Kavanaugh

4

object named as

Arthur Kavanaugh

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

author name string

Iain B McInnes

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Philip J Mease

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Bruce Kirkham

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Christopher T Ritchlin

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Proton Rahman

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Alice B Gottlieb

10

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Hanno Richards

11

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Luminita Pricop

12

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Gregory Ligozio

13

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Manmath Patekar

14

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Shephard Mpofu

15

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

FUTURE 2 Study Group

16

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

0 references

publication date

26 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

386

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

9999

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1137-1146

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The dual nature of TH17 cells: shifting the focus to function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-17 receptor and its functional significance in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Editorial: emerging evidence for critical involvement of the interleukin-17 pathway in both psoriasis and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Secukinumab in plaque psoriasis--results of two phase 3 trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-17 signaling in host defense against Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)61134-5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38989105&oldid=1935718852"